Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AZRX NYSE:OSTX NASDAQ:VIRI NASDAQ:WHWK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAZRXAzurRx BioPharma$2.32-11.8%$4.04$3.36▼$26.30$21.64M1.51628,703 shs48,104 shsOSTXOS Therapies$2.20+0.5%$1.93$1.12▼$7.00$69.62MN/A727,322 shs161,897 shsVIRIVirios Therapeutics$4.83-1.4%$4.86$0.13▼$1.04$93.02M1.581.05 million shs5,412 shsWHWKWhitehawk Therapeutics$1.79-0.6%$1.82$1.39▼$3.81$84.36M0.51146,853 shs26,150 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAZRXAzurRx BioPharma-2.59%+15.60%+620.75%+346.52%+557.50%OSTXOS Therapies-2.23%-1.79%+26.59%+15.87%-47.48%VIRIVirios Therapeutics0.00%-1.21%+0.20%-0.61%+2,607.18%WHWKWhitehawk Therapeutics+0.56%-1.10%+2.86%+179,999,900.00%+179,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAZRXAzurRx BioPharma$2.32-11.8%$4.04$3.36▼$26.30$21.64M1.51628,703 shs48,104 shsOSTXOS Therapies$2.20+0.5%$1.93$1.12▼$7.00$69.62MN/A727,322 shs161,897 shsVIRIVirios Therapeutics$4.83-1.4%$4.86$0.13▼$1.04$93.02M1.581.05 million shs5,412 shsWHWKWhitehawk Therapeutics$1.79-0.6%$1.82$1.39▼$3.81$84.36M0.51146,853 shs26,150 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAZRXAzurRx BioPharma-2.59%+15.60%+620.75%+346.52%+557.50%OSTXOS Therapies-2.23%-1.79%+26.59%+15.87%-47.48%VIRIVirios Therapeutics0.00%-1.21%+0.20%-0.61%+2,607.18%WHWKWhitehawk Therapeutics+0.56%-1.10%+2.86%+179,999,900.00%+179,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAZRXAzurRx BioPharma 0.00N/AN/AN/AOSTXOS Therapies 3.00Buy$18.00718.18% UpsideVIRIVirios Therapeutics 2.00Hold$5.003.52% UpsideWHWKWhitehawk Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest AZRX, VIRI, WHWK, and OSTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/27/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/20/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/11/2025WHWKWhitehawk TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell8/7/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.007/14/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.006/30/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.006/24/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAZRXAzurRx BioPharmaN/AN/AN/AN/A($0.76) per shareN/AOSTXOS TherapiesN/AN/AN/AN/AN/AN/AVIRIVirios TherapeuticsN/AN/AN/AN/A$0.20 per shareN/AWHWKWhitehawk Therapeutics$25.98M3.25N/AN/A$2.12 per share0.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAZRXAzurRx BioPharma-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/AOSTXOS Therapies-$7.79M-$0.79N/AN/AN/AN/AN/A-569.57%N/AVIRIVirios Therapeutics-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%N/AWHWKWhitehawk Therapeutics-$63.69M-$0.06N/A∞N/A99.42%-75.99%-68.57%N/ALatest AZRX, VIRI, WHWK, and OSTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025WHWKWhitehawk Therapeutics$0.49-$0.76-$1.25-$0.76$100.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAZRXAzurRx BioPharmaN/AN/AN/AN/AN/AOSTXOS TherapiesN/AN/AN/AN/AN/AVIRIVirios TherapeuticsN/AN/AN/AN/AN/AWHWKWhitehawk TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAZRXAzurRx BioPharmaN/A1.331.33OSTXOS TherapiesN/A0.760.76VIRIVirios TherapeuticsN/A7.277.27WHWKWhitehawk TherapeuticsN/A20.4120.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAZRXAzurRx BioPharma6.27%OSTXOS TherapiesN/AVIRIVirios Therapeutics9.05%WHWKWhitehawk Therapeutics52.08%Insider OwnershipCompanyInsider OwnershipAZRXAzurRx BioPharma7.30%OSTXOS Therapies10.30%VIRIVirios Therapeutics12.20%WHWKWhitehawk Therapeutics49.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAZRXAzurRx BioPharma129.33 million8.65 millionNot OptionableOSTXOS TherapiesN/A31.65 millionN/AN/AVIRIVirios Therapeutics519.26 million16.91 millionOptionableWHWKWhitehawk Therapeutics2147.13 million23.61 millionN/AAZRX, VIRI, WHWK, and OSTX HeadlinesRecent News About These CompaniesWhitehawk Therapeutics to Participate in Upcoming Investor ConferencesSeptember 2, 2025 | prnewswire.comWhitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Misses Expectations By $1.25 EPSAugust 10, 2025 | marketbeat.comWhitehawk Therapeutics (NASDAQ:WHWK) Downgraded to "Strong Sell" Rating by Wall Street ZenAugust 10, 2025 | marketbeat.comWhitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent HighlightsAugust 7, 2025 | prnewswire.comWhitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 22, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAZRX, VIRI, WHWK, and OSTX Company DescriptionsAzurRx BioPharma NASDAQ:AZRXAzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.OS Therapies NYSE:OSTX$2.20 +0.01 (+0.46%) Closing price 04:00 PM EasternExtended Trading$2.14 -0.06 (-2.91%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.Virios Therapeutics NASDAQ:VIRI$4.83 -0.07 (-1.43%) As of 09/9/2025Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.Whitehawk Therapeutics NASDAQ:WHWK$1.79 -0.01 (-0.56%) As of 04:00 PM EasternAadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Forget QQQ: This ETF Marries the Magnificent 7 and Communications Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
